Navigation Links
Standardized protocols would greatly enhance clinical and research potential of BTMs
Date:12/27/2010

An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and recommends that specific markers be used as reference analytes for BTMs in clinical and observational studies.

BTMs have been extensively studied in relation to fracture risk assessment and have been found, in some cases, to predict fracture risk independently of bone mineral density (BMD). However, the use of different markers and a number of measurement methods, even for the same marker, has resulted in incomparable and inconsistent data and therefore currently limits the incorporation of BTMs in fracture risk prediction tools, such as FRAX.

In clinical practice, BTMs are used to monitor osteoporosis treatment. BTMs generally show large and rapid responses to the treatments used for osteoporosis, which make them an appealing tool to inform physicians and patients on treatment efficacy. Some evidence suggests that changes in BTMs following treatment with antiresorptive agents may explain a greater percentage of the fracture risk reduction than does the change in BMD. However, further population studies, with correct sample handling and statistical methods, are needed to confirm these findings.

In its position paper* the Joint IOF-IFCC Bone Marker Standards Working Group identified several research priorities to address the gaps in the literature. It recommends that specific markers of bone formation (s-PINP) and of bone resorption (s-CTX) be used as reference analytes for bone turnover markers in clinical and observational studies. Professor Cyrus Cooper, Co-chair of the Joint IOF-IFCC Bone Marker Standards Working Group and Chair of the IOF Committee of Scientific Advisors, stated "Whilst no perfect 'gold standard' marker exists, these were chosen based on a number of criteria. These include adequate characterisation and clear definition of the marker; their specificity for bone and performance in clinical studies; wide availability; biological and analytical variability; sample handling; stability; ease of analysis and availability of method in routine laboratories; and the medium of measurement (urine vs. serum)."

Professor John Kanis, IOF President, urged the adoption of the reference standards by the scientific community, "Without precluding the use of other BTMs, the adoption of these reference standards would facilitate comparison between studies and allow data from different studies to be pooled in order to facilitate their incorporation into routine clinical practice." He also noted that standardised protocols would greatly increase the clinical and research potential of BTMs, with improved value in patient management and other uses, such as prediction of the rate of bone loss, identification of secondary osteoporosis, prediction of response to therapy, and in improving treatment adherence.


'/>"/>

Contact: L. Misteli
lmisteli@iofbonehealth.org
41-229-940-100
International Osteoporosis Foundation
Source:Eurekalert

Related biology news :

1. Special issue of BMC Microbiology spotlights standardized language for describing microbes
2. Cold Spring Harbor Protocols features organ and cell culture methods
3. Methods for studying DNA repair and protein modification are featured in CSH Protocols
4. Cold Spring Harbor Protocols features stem cell differentiation, plant RNAi methods
5. Protein function and chromatin structure methods featured in Cold Spring Harbor Protocols
6. Basic guides to PCR, labeling neurons featured in Cold Spring Harbor Protocols
7. Protein analysis methods, viral vectors featured in Cold Spring Harbor Protocols
8. Methods for gene transfer in stem cells featured in Cold Spring Harbor Protocols
9. Cold Spring Harbor Protocols features RNA analysis methods
10. High-throughput analysis of gene regulation, DNA synthesis in Cold Spring Harbor Protocols
11. High-throughput genotyping, protein purification featured in Cold Spring Harbor Protocols
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... TRIANGLE PARK, N.C., Feb. 22, 2017  United Therapeutics ... its financial results for the fourth quarter and ... 2016 financial results reflect continued growth as net ... million," said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... our ability to develop and advance our growing ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... to build connected digital health applications, announced a partnership with Redox, a leader ... seamlessly connect to many clinical systems while keeping data secure in the cloud. ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics ... has joined its executive team to lead the development and commercialization of its ... help improve the diagnosis and treatment of cancer. The CIDT addresses the need ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... and utilizing the experience of both in-house personnel and consultants, VetStem constructed and ...
Breaking Biology Technology: